A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Clinical trial NCT05276297 · COMPLETED

Trial details

NCT number: NCT05276297
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatitis B, Chronic

Start date: 2022-03-22
Primary completion: 2025-08-05
Enrollment: 174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.